Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials

Leuk Lymphoma. 2015;56(9):2747-9. doi: 10.3109/10428194.2015.1010079. Epub 2015 Feb 17.

Authors

Ashley Marton¹, Abbas Kezouh², Tina Petrogiannis-Haliotis³, Sarit Assouline⁴

Affiliations

¹ a Department of Hematology , McGill University , Montreal , Quebec , Canada.
² b Department of Epidemiology , Jewish General Hospital , Montreal , Quebec , Canada.
³ c Department of Pathology , Jewish General Hospital , Montreal , Quebec , Canada.
⁴ d Department of Hematology , Jewish General Hospital , Montreal , Quebec , Canada.

PMID: 25651426
DOI: 10.3109/10428194.2015.1010079

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials as Topic*
Cyclophosphamide / therapeutic use
Disease Progression
Doxorubicin / therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Large B-Cell, Diffuse / mortality
Lymphoma, Large B-Cell, Diffuse / pathology*
Lymphoma, Large B-Cell, Diffuse / therapy*
Patient Selection*
Prednisone / therapeutic use
Research Design
Rituximab
Transplantation, Autologous
Treatment Outcome
Vincristine / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone